Cullinan Therapeutics, Inc. (CGEM) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-05-06

Key Insights

Chief Scientific Officer Jennifer Michaelson executed a net sale of 8,000 shares (7,800 + 200) while simultaneously acquiring 4,000 shares through stock option exercise, indicating a net reduction in beneficial ownership from 174,844 to 166,844 shares.
The sales were executed under a Rule 10b5-1 trading plan established on August 7, 2025, suggesting these transactions were pre-planned and not reactive to current market conditions, which reduces concerns about negative insider sentiment.
Sales occurred at significantly higher prices ($14.60-$15.58 range) compared to the option exercise price of $4.30, representing substantial unrealized gains being monetized by company leadership.
The stock option vesting schedule shows 25% cliff vesting on July 4, 2020, with remaining shares in 36 monthly installments, indicating long-term incentive alignment, though the officer is now liquidating a portion of accumulated equity.

Want the newest filings?

This analysis covers the filing from 2026-05-06. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-03-09

Insider Jennifer Michaelson, the Chief Scientific Officer, exercised 4,000 stock options and sold 8,000 shares, suggesting she is monetizing a portion of her equity holdings.
The sale of shares was executed pursuant to a pre-arranged 10b5-1 trading plan, indicating the transactions were planned in advance and not driven by immediate liquidity needs.
The reported transactions represent a relatively small portion of Michaelson's total beneficial ownership of 170,844 shares, suggesting she maintains a significant equity stake in the company.

Filed: 2026-02-26

Jennifer Michaelson, the Chief Scientific Officer, sold 1,780 shares of Cullinan Therapeutics, Inc. (CGEM) on February 25, 2026 at a weighted average price of $14.14 per share.
The sale was made pursuant to a 10b5-1 trading plan established on August 7, 2025, suggesting planned selling activity.
Following the reported transaction, Michaelson continues to hold 174,844 shares, maintaining a significant ownership stake in the company.

Filed: 2026-02-25

The reporting person, Jennifer Michaelson, who is the Chief Scientific Officer of Cullinan Therapeutics, Inc. (CGEM), has sold 5,353 shares of the company's common stock over the past two trading days, potentially indicating some insider selling activity.
The shares were sold at weighted average prices of $13.99 and $14.47, suggesting the reporting person may have been taking some profits on their holdings.
The reporting person still holds a significant number of shares (180,225) following the reported transactions, indicating they may maintain a substantial equity stake in the company.

Filed: 2026-02-25

The reporting person, Nadim Ahmed, who is the President and CEO of Cullinan Therapeutics, Inc. (CGEM), sold 13,515 shares of common stock on February 24, 2026 at a price of $14.47 per share.
The sale of shares appears to be for the purpose of covering personal income tax obligations upon the vesting of restricted stock units, as indicated in the filing.
Following the reported transaction, Nadim Ahmed continues to hold 390,803 shares of Cullinan Therapeutics' common stock directly.

Filed: 2026-02-25

Insider Jeffrey Alan Jones, the Chief Medical Officer, sold 4,582 shares of Cullinan Therapeutics (CGEM) at $14.47 per share on 2026-02-24. This sale was likely to cover personal income tax obligations upon vesting of his restricted stock units.
The reported transaction represents a relatively small portion of Jones' total beneficial ownership, which remains at 159,968 shares following the sale.
Insider sales can signal potential concerns about the company's outlook, but the timing and size of this transaction do not appear to be a significant cause for alarm.

Filed: 2026-02-25

The reporting person, Jacquelyn Sumer, who is the Chief Legal Officer of Cullinan Therapeutics, Inc., sold 3,601 shares of the company's common stock at $14.47 per share to cover personal income tax obligations upon the vesting of restricted stock units.
The transaction represents a relatively small portion of the reporting person's overall beneficial ownership, as they still hold 128,089 shares of the company's common stock.
The sale of shares to cover tax obligations is a common practice among company insiders and does not necessarily indicate a lack of confidence in the company's future prospects.

Filed: 2026-02-23

Jacquelyn Sumer, the Chief Legal Officer, sold 3,742 shares of Cullinan Therapeutics, Inc. (CGEM) stock on 2026-02-20 at $13.62 per share, likely to cover personal income tax obligations.
This transaction represents a relatively small portion (2.8%) of Sumer's total beneficial ownership of 131,690 CGEM shares, suggesting this was a routine sale and not a major change in her position.
The sale was executed in an open market transaction, indicating it was not part of a pre-planned 10b5-1 trading plan.

Filed: 2026-02-23

The reporting person, Jeffrey Alan Jones, has sold 4,982 shares of Cullinan Therapeutics, Inc. (CGEM) common stock at $13.62 per share to cover personal income tax obligations upon vesting of restricted stock units.
The reporting person's direct ownership in the company has decreased from 169,532 shares to 164,550 shares following this transaction.
This sale of shares by the Chief Medical Officer is likely to cover tax obligations and not a sign of negative sentiment towards the company.

Filed: 2026-02-23

Jennifer Michaelson, the Chief Scientific Officer, sold 3,742 shares of Cullinan Therapeutics stock to cover personal income tax obligations, indicating some liquidity needs.
Michaelson also exercised 8,000 stock options, suggesting she remains committed to the company and is converting her equity compensation.
The transactions were executed under a 10b5-1 trading plan, which indicates they were pre-scheduled and not based on any insider information.

Filed: 2026-02-23

Insider Nadim Ahmed, the President and CEO of Cullinan Therapeutics, sold 16,381 shares of the company's common stock to cover personal income tax obligations upon the vesting of restricted stock units.
This transaction reflects a reduction in Nadim Ahmed's direct beneficial ownership of Cullinan Therapeutics' common stock from 420,699 shares to 404,318 shares, a 3.9% decrease.
Insider selling transactions, even for tax purposes, can sometimes be perceived as a negative signal by investors, suggesting potential concerns about the company's future prospects.

Filed: 2026-02-23

Mary Kay Fenton, the Chief Financial Officer, sold 4,398 shares of Cullinan Therapeutics, Inc. (CGEM) at $13.62 per share, likely to cover personal income tax obligations.
Fenton's stock holdings decreased from 130,778 shares to 126,380 shares, indicating a small reduction in her direct equity ownership.
The sale was a routine transaction to satisfy tax obligations and does not necessarily signify a broader change in Fenton's long-term outlook on the company.

Filed: 2026-02-19

The filing indicates that Jacquelyn Sumer, the Chief Legal Officer of Cullinan Therapeutics, Inc. (CGEM), was granted a stock option to purchase 230,000 shares of the company's common stock on February 18, 2026.
The option has a 10-year term and vests over a 4-year period, with 1/48th of the shares vesting monthly, indicating a long-term incentive for the executive.
Insider stock option grants can signal management's confidence in the company's future prospects and potential for growth.

Filed: 2026-02-19

Insider Jeffrey Alan Jones, the Chief Medical Officer, acquired 300,000 stock options, representing a significant increase in his ownership stake in the company.
The options have a 10-year term and vest over 4 years, indicating a long-term commitment from the executive.
The exercise price of $12.44 per share is in line with the current market price, suggesting the options were granted at fair market value.

Filed: 2026-02-19

The CEO Nadim Ahmed has been granted a large stock option award of 828,000 shares, which vests over 4 years. This indicates confidence in the company's long-term growth prospects.
The stock option grant is priced at $12.44 per share, which is the current market price and suggests the compensation is aligned with shareholder interests.
The filing does not indicate any insider selling, suggesting the leadership team remains committed to the company's success.

Filed: 2026-02-19

The reporting person, Corrine Savill, was granted a stock option to acquire 175,000 shares of Cullinan Therapeutics, Inc. common stock on February 18, 2026, with a vesting schedule of 1/48th per month over 4 years.
This stock option grant indicates that Corrine Savill, who holds the position of Chief Business Officer, is being incentivized and retained by the company through equity-based compensation.
The exercise price of the stock option is $12.44 per share, which suggests the company's stock price is trading at that level or higher as of the grant date.

Other reports for Cullinan Therapeutics, Inc.

Quarterly Report Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.